Chemical Namebelantamab mafodotin
Dosage FormInjection; (Iintravenous; 100mg)
Drug ClassAntineoplastics
CompanyGlaxoSmithKline plc
Approval Year2020


  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last updated on 12/7/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Blenrep (belantamab mafodotin-blmf) Prescribing Information.2020GlaxoSmithKline Research, Triangle Park, NC
Document TitleYearSource
Assessment report: Blenrep.2020European Medicines Agency